Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (2.618)

1

Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA

enthalten in: PharmacoEconomics | 2024

von Lin, S. | Shapouri, S. | Parisé, H. | +4

2

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

enthalten in: Cancer biology & therapy | 2024

von Wang, H. | Koob, T. | Fromm, J. | +3

3

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors

enthalten in: Clinical and translational science | 2024

von Robbrecht, D. | Grob, J. | Bechter, O. | +20

4

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer : The Neotorch Randomized Clinical Trial

enthalten in: JAMA | 2024

von Lu, S. | Zhang, W. | Wu, L. | +63

5

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma : The JUPITER-02 Randomized Clinical Trial

enthalten in: JAMA | 2023

von Mai, H. | Chen, Q. | Chen, D. | +37

CommentIn: JAMA. 2023 Nov 28;330(20):1954-1955. - PMID 38015229

6

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer : TROPION-PanTumor01

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Shimizu, T. | Sands, J. | Yoh, K. | +14

7

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

enthalten in: Journal for immunotherapy of cancer | 2023

von Leidner, R. | Conlon, K. | McNeel, D. | +11

8

AdvanTIG-105 : a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

enthalten in: Journal for immunotherapy of cancer | 2023

von Frentzas, S. | Kao, S. | Gao, R. | +6

9

Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer

enthalten in: Clinical breast cancer | 2023

von Graff, S. | Yan, F. | Abdou, Y.

10

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

enthalten in: Journal for immunotherapy of cancer | 2023

von Brignole, C. | Calarco, E. | Bensa, V. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[262]